Livzon Pharmaceutical Group Inc.

000513

CNE0000002Y8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
39.41 ^CNY	+1.10%		+5.04%	+12.57%

Apr. 26	Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	CI
Apr. 24	Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	MT

Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.

April 02, 2024 at 12:00 pm EDT

From January 18, 2024 to March 31, 2024, the company has repurchased 2,476,300 shares, representing 0.27% for HKD 60.36 million. With this, the company has completed the repurchase of 2,476,300 shares, representing 0.27% for HKD 60.36 million under the buyback announced on January 19, 2024.

Latest news about Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	Apr. 26	CI
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	Apr. 24	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 23	CI
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.	Apr. 02	CI
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	Mar. 29	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	Mar. 28	CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	Feb. 23	MT
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	Feb. 22	CI
Livzon Pharma Gets Nod to Trial Weight Management Drug	Feb. 05	MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President	Jan. 30	MT
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	Jan. 18	CI
Livzon Pharma Recognizes Credit, Asset Impairments	Jan. 10	MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical	Jan. 02	MT
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics	Dec. 18	MT
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List	Dec. 14	MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	Dec. 04	MT
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use	Dec. 03	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 5% stake in Zhuhai Livzon Diagnostics Inc. from Shi Jianfeng.	Nov. 20	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin.	Nov. 20	CI
Livzon Pharma Boosts Stake in Diagnostic Equipment Unit Ahead of Spinoff	Nov. 20	MT
Zhuhai Livzon Biomedical Technology Co., Ltd announced that it expects to receive CNY 1 billion in funding from Livzon Pharmaceutical Group Inc.	Nov. 16	CI
Livzon Pharmaceutical Group Inc. entered into share purchase agreement to acquire an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin for CNY 24.57 million.	Nov. 16	CI
Livzon Pharmaceutical Group Inc. entered into Equity Transfer Agreement to acquire an additional 5% stake in Zhuhai Livzon Diagnostics Inc. from Shi Jianfeng for CNY 41 million.	Nov. 16	CI
Livzon Pharmaceutical Submits Application to Hong Kong Bourse for Spin-Off, Separate Listing of Controlling Subsidiary	Nov. 14	MT

Chart Livzon Pharmaceutical Group Inc.

Duration

Period

More charts

Company Profile

LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Livzon Pharmaceutical Group Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

39.41 CNY

Average target price

41.14 CNY

Spread / Average Target

+4.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIVZON PHARMACEUTICAL GROUP INC.	+12.57%	4.38B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+27.42%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.43%	234B
NOVARTIS AG	+4.72%	199B
ROCHE HOLDING AG	-10.35%	196B
AMGEN INC.	-4.04%	148B

Other Pharmaceuticals

Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

Pharmaceuticals

Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.

EPS Revisions